SecBot SecBot
Biotech Drug Report Generated Aug 20, 2026

TLX101-Tx

TLX·Telix Pharmaceuticals Limited
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 3 (pivotal, just initiated); Phase 1 safety stage complete
Time to market
Unknown, likely several years. Phase 3 (IPAX BrIGHT) began dosing in April 2026; no primary-completion or readout date has been disclosed, so approval (if trials succeed) is not expected before ~2030.
Why 3/10
No hard, dated binary catalyst for TLX101-Tx in the next ~12 months: the pivotal Phase 3 IPAX BrIGHT trial only dosed its first patient in April 2026 (readout years away), and the Phase 1 IPAX-2 safety readout (enrollment complete, no dose-limiting toxicities) is already out, so the program is a mid-stage asset with no pending regulatory decision at a diversified commercial-stage company, scoring a 3.
Actionable Insight NEUTRAL

TLX101-Tx itself has no near-term stock catalyst, the Phase 3 IPAX BrIGHT trial (recurrent glioblastoma) just began enrolling, so the next meaningful events are enrollment/timeline updates, likely at Telix's R&D Day on September 22, 2026. Investors holding TLX should treat TLX101-Tx as a long-dated pipeline option; near-term share-price drivers are the commercial business (H1 2026 revenue $477M) and the September 11, 2026 PDUFA for the separate diagnostic TLX101-Px (Pixclara), not this therapy.

Price Chart

Loading chart...

Executive Summary

TLX101-Tx (131I-iodofalan) is Telix Pharmaceuticals' investigational radiopharmaceutical therapy for glioblastoma (GBM), the most aggressive form of brain cancer. It is an early-to-mid-stage program: a Phase 1 trial (IPAX-2) finished enrollment in May 2026 with a clean safety profile (no dose-limiting toxicities at the maximum dose), and the pivotal Phase 3 trial (IPAX BrIGHT) in recurrent GBM dosed its first patient in April 2026, making it, per Telix, the first radiopharmaceutical therapy to reach Phase 3 for GBM. There is no near-term approval or readout catalyst for this specific drug; it sits inside a diversified, profitable, commercial-stage radiopharma company (TLX, ~$12.12; analyst mean price target ~$21.29) whose near-term share-price drivers are commercial results and a September 2026 PDUFA for a separate diagnostic (TLX101-Px/Pixclara).

How It Works

TLX101-Tx is a targeted radiation therapy for brain cancer: a radioactive iodine atom (iodine-131, which emits cell-killing beta radiation) attached to an amino-acid-like molecule (iodofalan). Glioblastoma cells take up this amino-acid mimic through the same transport pathways they use for nutrients, so the radiation is concentrated inside tumor cells rather than delivered as whole-body or whole-brain radiation, an approach called theranostics, because the same biology used to image the tumor (Telix's FET PET tracer) is used to target the therapy.

Trial Status

Phase 1 IPAX-2 trial in newly diagnosed glioblastoma completed patient enrollment in May 2026 with no dose-limiting toxicities observed at any dose level, including the maximum 2 x 5 GBq (10 GBq total). The pivotal Phase 3 IPAX BrIGHT trial in recurrent glioblastoma, described by Telix as the first radiopharmaceutical therapy to enter Phase 3 for GBM, dosed its first patient in April 2026. No efficacy results have been reported for either trial.

The Two-Sided Case

▲ Bull Case5
First-mover status: Telix says TLX101-Tx is the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma, a disease with a huge unmet need (per April 2026 first-patient-dosed release).
Phase 1 de-risking: IPAX-2 completed enrollment in May 2026 with no dose-limiting toxicities observed at any dose, including the maximum 2 x 5 GBq (10 GBq total), a positive safety signal ahead of the pivotal trial.
Theranostic franchise: pairs with Telix's brain-tumor imaging candidate (TLX101-Px/FET PET) and a June 2026 neuro-oncology webinar signals a deliberate GBM franchise build, not a one-off program.
Well-funded developer: Telix is commercial-stage and profitable, H1 2026 revenue US$477M (+22% YoY) and net profit US$38M vs a loss a year earlier, with FY26 revenue guidance at the upper end of US$950-970M, so the Phase 3 is not financing-dependent.
Institutional accumulation in 2026-Q2: UBS roughly quadrupled (sharesChangePct +317%), BlackRock doubled (+201%), Morgan Stanley added (+42.5%), JPMorgan added (+35.2%), per 13F changes.
▼ Bear Case5
No near-term catalyst: the pivotal Phase 3 only started enrolling in April 2026 and efficacy results are years away, a long, unresolved binary with no dated readout in the next ~12 months.
GBM is a graveyard indication: recurrent glioblastoma has seen many late-stage failures; the efficacy bar (overall survival) is high and the recurrent setting is especially hard.
Small slice of a big company: TLX101-Tx is one of several therapy programs (TLX591-Tx prostate, TLX250-Tx renal, TLX597-Tx) at a company already driven by commercial products, even clean Phase 1 news (May 2026) was assessed as only a modest stock driver.
Competition: established GBM treatments (temozolomide chemo, tumor-treating fields, bevacizumab in recurrence) plus many other investigational candidates crowd the field.
Company-level overhangs: Telix set up an ATM facility (potential equity dilution) and refinanced with a US$600M convertible bond, and local FINRA flow data showed an elevated weighted short-volume ratio (~0.41 in late June 2026), execution-flow context, not outstanding short interest.

Upcoming Catalysts

  • Telix R&D Day in New York, September 22, 2026, likely venue for IPAX BrIGHT enrollment/timeline guidance and any early TLX101-Tx data
  • IPAX BrIGHT (Phase 3, recurrent GBM) enrollment progress and any interim updates
  • Company-level, not this drug: FDA PDUFA date of September 11, 2026 for the separate diagnostic TLX101-Px (Pixclara); H1 2026 results already released August 20, 2026
  • Any announcement of IPAX-1/IPAX-2 efficacy or translational data

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Telix Pharmaceuticals Limited PRESS-RELEASE TLX ·Originating report

Sources · 9

Hover a chip for the title
1 globenewswire.com2 sec.gov3 sec.gov4 globenewswire.com5 globenewswire.com6 globenewswire.com7 sec.gov8 globenewswire.com9 globenewswire.com